[{"_1":2,"_112":-5,"_113":-5},"loaderData",{"_3":4,"_26":27},"root",{"_5":6,"_17":10,"_18":19,"_20":21,"_22":10,"_23":-5,"_24":-5,"_25":10},"user",{"_7":8,"_9":10,"_11":10,"_12":-5,"_13":-5,"_14":15,"_16":-5},"roles",[],"isAuthenticated",false,"isPremium","planName","subscriptionStatus","featureFlags",{},"insightsBudget","isDevelopmentHost","userPreferences",{},"recaptchaSiteKey","6LcvOJcUAAAAAHsB-gPGfGktcRlKpH7OTIU_dMTD","isImpersonating","impersonation","affiliateStatus","isFreedomPortal","routes/v2/article/layout",{"_28":29,"_30":31},"notFound",true,"relatedArticles",[32,76,88,100],{"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":48,"_49":50,"_51":52,"_53":54,"_55":56,"_57":58,"_59":60,"_61":62,"_63":64,"_65":66,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},"mediaId",6528085,"mediaKeyId","3473882-e12be34b17c77ae4df68cebf414939ff","parentId",3473882,"title","CPRIT approves six prevention awards to expand screening, navigation and HPV vaccination in underserved Texas areas","audioSeconds",537,"startMs",4531000,"endMs",5068000,"viewUrl","/Search/View?dp=1&key=3473882-e12be34b17c77ae4df68cebf414939ff&start=4531&end=5068","thumbnailUrl","https://assets.pipeline.soar.com/3473882-e12be34b17c77ae4df68cebf414939ff/thumbnail_4531000.jpg","articleUrl","/articles/6528085/Texas/CPRIT-approves-six-prevention-awards-to-expand-screening-navigation-and-HPV-vaccination-in-underserved-Texas-areas","mediaUrl","https://secure.pipeline.soar.com/6528085-13e8b04627cccd23dbd6a2170172ac0a/orig.mp4?Expires=1770995352&Signature=XxHp5d0J7D6A4VskqjrJ-ff7ljY7ZTx1npGddUk0S-92Ql1NzDobDKUUcWEkf67jETI5UWpmIfESAKHlNrOMu4vN09lnyAxCvqVcKP5hYdqrvLQ4vq85GPrvzX59yKqA14w71847jQFClU297H2d1tiYwjzEf-SPGmMlWOgUXGBgFuyRPAfSULE4Z6rJrH0mjxlYxWWZbIMtfklkAAkE8hnTnD6WykeFwmDVLbJYlYEVJcQrq4jaznMYOvPf2YtLKQDNc8mx7g~4FrwQq840mcMBmF-EnQS30q~XlnGEQCJMu7L6C7aSfSCBpe9x1lBmrzXUYUTW06v7PhY-K7BXaQ__&Key-Pair-Id=KUT5TJCACFTXG","author","Cancer Prevention and Research Institute of Texas (CPRIT)","date","2025-05-21T00:00:00Z","article","The CPRIT oversight committee approved six prevention grant recommendations during its May 21 meeting. The Prevention Integration Committee recommended four cancer-screening/early-detection awards and two primary-prevention awards.

Why this matters: Prevention awards fund community-based screening, patient navigation and vaccination efforts that target underserved and rural counties in Texas and aim to increase screening uptake and follow-up care.

Award highlights
- PP25-052 (BEST program), Texas Tech University Health Sciences Center at El Paso — maintenance-expansion breast cancer education, screening and navigation program covering more than 30 counties in West and South Texas; adds community partnerships and referral networks including social services and transportation supports.
- PP25-053 (SUCCESS III), Texas Tech University Health Sciences Center at El Paso — maintenance-expansion colorectal screening program covering more than 40 counties; noted national recognition for screening and follow-up success.
- PP25-004 (C-STEP), Texas A&M University Health Science Center — maintenance-expansion interdisciplinary cancer prevention program for rural and medically underserved women in 25 counties; expands training for family physicians, residents and community health workers; includes mobile mammography and partnerships with FQHCs.
- PP25-075, Texas Southern University — breast cancer screening and prevention center focusing on uninsured/underinsured African American and other minority women in nine counties; uses mobile units and local partnerships.
- PP25-072, UT Health Science Center at San Antonio — multi-component community intervention to increase HPV vaccination among adolescents in Bexar County, adopting the All4Them program and adding CHW training and clinic events.
- PP25-056, UTMB Galveston — expanding HPV vaccination opportunities and education in medically underserved areas of East Texas; includes provider education, outreach events and partnerships with regional medical societies and Area Health Education Centers.

Vote and implementation notes
- The oversight committee approved the six prevention awards in a single vote and delegated contract negotiation and signature authority to the CEO and CPRIT staff.
- Management will negotiate contracts and set implementation schedules; staff identified expected modest counts (5–10 awards submitted for these mechanisms in pilot phases) and noted plans for outreach and webinars to increase awareness among community and clinical partners.

Quotes
- “This program covers over 30 counties in West And South Texas,” prevention presentation (BEST program description).
- “We don't expect to get a huge number of grants. It's probably more likely to be between 5 and 10,” prevention staff (on pilot clinical trial capacity awards for rural/underserved areas).

Next steps
- Contracts will be negotiated and executed under delegated authority; prevention staff will implement the programs and provide compliance and outcome reports as required.","mediaType","Video","parentTitle","CPRIT Oversight Committee Meeting (May 21, 2025)","oneSentenceSummary","The oversight committee approved six prevention grants totaling multiple maintenance‑expansion and implementation projects focused on breast, colorectal, cervical and HPV vaccination outreach across West, South and East Texas and Bexar County.","taxTitle","Cancer Prevention and Research Institute of Texas (CPRIT), Departments and Agencies, Executive, Texas","taxId",17113,"location","Texas","headline","","shortSummary",{"_33":77,"_35":36,"_37":38,"_39":78,"_41":79,"_43":80,"_45":81,"_47":82,"_49":83,"_51":84,"_53":85,"_55":56,"_57":58,"_59":86,"_61":62,"_63":64,"_65":87,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},6528089,"CPRIT awards supplemental product-development funding to eight companies; OncoResponse equity tranche contingent on clinical milestone",545,5251000,5796000,"/Search/View?dp=1&key=3473882-e12be34b17c77ae4df68cebf414939ff&start=5251&end=5796","https://assets.pipeline.soar.com/3473882-e12be34b17c77ae4df68cebf414939ff/thumbnail_5251000.jpg","/articles/6528089/Texas/CPRIT-awards-supplemental-product-development-funding-to-eight-companies-OncoResponse-equity-tranche-contingent-on-clinical-milestone","https://secure.pipeline.soar.com/6528089-3d5961d5a9e089c6bdd44d89b240d483/orig.mp4?Expires=1770995352&Signature=ZLMtb4UJD5vG8284hzisuhB7WYqhGf9IS3jCxklVIECeH53f38JCAC7sUpJqVit-yOjq5o6w6GxmtYAtjE5SChkh5VvYvePcw9ioMaB8R6kHGYU3rUGxH5fO92WKQuuA6DM7vLeIZDvk34kCuXuGpFNnGj40bs0gYNWprDqsvrVEKwF7N6iCaF5dvhxWs7WzV-gt9zUB0WOHut5-gyOorGV9msieFRAiTZ~f7Eb6JoOWRQKFw-Qp~w7WYD5kVUwwsg9ym9juxCxmELD8zAaEKoNBlSulAOkm2B1otxXK5l7MSV4c0WiFLg~5mRbR6VOqW6HoaBgo51JQdOTOcdhT1g__&Key-Pair-Id=KUT5TJCACFTXG","The oversight committee approved supplemental product-development awards for companies that already held active CPRIT grants, using a carryover pool of roughly $10 million.

Why this matters: The supplemental funding aims to accelerate commercialization activities and clinical progress for companies already in CPRIT’s portfolio. CPRIT approved advanced payments contingent on contract execution and tranche conditions.

What the product-development presentation said
- Pool and approach: CPRIT staff used about $10 million of carryover from FY25 product-development funds to provide supplemental awards to existing CPRIT-funded companies. The RFA limited awards to a maximum total supplemental request (no single supplemental award above specified percentage rules for seed-stage recipients).
- Selection: 23 companies applied, 12 were interviewed and rank-ordered; seven companies received full supplemental awards in FY25 and one company received a partial tranche; remaining funds will be allocated in 26.1.

Companies and program use described in the presentation (spelling as presented in transcript)
- OncoResponse: clinical milestone–contingent equity tranche (clinical milestone: outcome from initial small patient cohort) that could trigger an additional $3 million from the FY26 pool if the milestone is met.
- InForm AI: AI-driven radiation therapy planning platform to expand clinical validation and integration with treatment planning systems.
- Ultram Therapeutics: monoclonal antibody program targeting CD127 for hematological malignancies; expansion into Phase 2a clinical study planned.
- Instapath: fluorescence-based fresh tissue imaging platform; supplemental funds for prototype production and pilot clinical evaluation.
- Rapamycin Holdings: an improved rapamycin formulation (eRAPA) being developed for familial adenomatous polyposis (FAP); Phase 3 expansion noted and Fast Track designation referenced.
- Out of MINDS (as presented in transcript): scaling production of high-purity medical isotopes (ytterbium-176) and validating commercial production.
- Pranatha Vrassik (as presented in transcript): METERCore device developer for minimally invasive excision of small lung nodules; funds to expand first-in-human study and regulatory milestones.
- Resilience: manufacturing platforms for cell therapies and vector production; supplemental support to scale Texas-based manufacturing and partnerships.

Financial and procedural notes
- Total carryover available for supplemental awards was presented as approximately $10,000,000. The oversight committee approved seven companies for FY25 disbursements and the eighth package received partial funding to be completed in FY26 pending milestone completion.
- The committee authorized advanced payments (disbursements in advance) upon execution of contract documents and successful completion of tranches for the eight companies.

Vote and next steps
- The oversight committee approved the supplemental awards and delegated contract negotiation and signature authority to the CEO and CPRIT staff. Staff will negotiate award terms, equity/tranche conditions (where applicable), and start the contracting process. CPRIT authorized advanced payments upon contract execution and tranche satisfaction.","CPRIT approved supplemental awards for product development using a roughly $10 million carryover pool. The agency prioritized existing grantees; OncoResponse received a conditional equity tranche tied to a clinical milestone.",{"_33":89,"_35":36,"_37":38,"_39":90,"_41":91,"_43":92,"_45":93,"_47":94,"_49":95,"_51":96,"_53":97,"_55":56,"_57":58,"_59":98,"_61":62,"_63":64,"_65":99,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},6528090,"CPRIT approves 47 academic research awards totaling $69.7 million; committee debates early-onset cancer priorities",3414,1103000,4517000,"/Search/View?dp=1&key=3473882-e12be34b17c77ae4df68cebf414939ff&start=1103&end=4517","https://assets.pipeline.soar.com/3473882-e12be34b17c77ae4df68cebf414939ff/thumbnail_1103000.jpg","/articles/6528090/Texas/CPRIT-approves-47-academic-research-awards-totaling-697-million-committee-debates-early-onset-cancer-priorities","https://secure.pipeline.soar.com/6528090-54192cf2398e1f5749d7c39764e14709/orig.mp4?Expires=1770995352&Signature=is7g6Cabd6kQkL-3aSu0wv-0FzBaSBVEwbuQH6UpuVRN3ZOVz1uFqntU0ntUnkwR46Tsi21De8ZdjnEMo7KWfJmUzcimEsEC-1WYLpFsoIHeuXEVBjdWkR9ce1YDp0RvzujdblDWEgXMNhvM15UybaQZF7Ere5YnLuLgcae16dxRERDLb~GazJ64gxf52WVhNP7Qpbe5oB8bqjhY0W0DIFPpiPQK-S2zuTr7GXVS4Z3s9EO-HFsoLsBnp8YiNS1M~Bb40cSKr75IBQkqj693eSckEX2UpsWKkKAYWfnEAmyStdKHGxcevNJ5AerNnYjB13hGAX7e87hcG96zdAIGEQ__&Key-Pair-Id=KUT5TJCACFTXG","The Cancer Prevention and Research Institute of Texas Oversight Committee approved the Program Integration Committee's (PIC) slate of 47 academic research awards totaling $69.7 million during its May 21 meeting.

Why this matters: The awards support investigator-initiated research, core facilities and investigator recruitment across Texas institutions and are intended to strengthen the state's cancer research capacity and clinical-translational pipeline.

Key details of the PIC recommendation
- Number and total: 47 awards across eight grant mechanisms requesting $69,700,000.
- Notable slates included core facility support (11 recommended from 19 submissions), high-impact/high-risk research (17 recommended), early clinical investigator awards (3 recommended), TRAC/TRAC-eligible institution awards (including a single-cell genomics award), and multiple recruitment awards for established and first-time tenure-track investigators.
- The PIC emphasized core facilities that serve multiple institutions and TRAC-eligible institutions, and selected grants supporting drug discovery and unique capabilities such as extracellular vesicle research.

Discussion highlights
- Early-onset cancers: Committee members including Doctor Rosenfeld and Doctor Rice urged that early-onset cancers (younger adults with colorectal, breast and other cancers) be considered for elevated priority; Doctor LeBeau noted CPRIT had issued investigator-initiated awards for early-onset cancer previously and acknowledged interest in increasing focus.
- Geographic diversity and TREC: Members discussed geographic concentration of recruitment awardees in Houston and urged outreach to institutions outside the I-35 corridor and to TRAC-eligible institutions.
- Recruitment: The committee discussed internal recruitment awards (supporting moves within the same institution when the faculty appointment moves departments) and the rationale for using recruitment funding to retain rising stars who might otherwise leave Texas.

Vote and procedural notes
- The oversight committee voted to approve the PIC recommendations. Doctor Rosenfeld disclosed a conflict on RP250601 and did not vote on that single recommendation; the committee approved RP250601 in a separate vote by the required two-thirds and then approved the remaining 46 recommendations in a subsequent vote. The chair later delegated negotiation and signature authority to the CEO and CPRIT staff for the approved awards.

Quotes
- “These include 47 awards requesting $69,700,000,” Doctor Dawn LeBeau (academic research update).
- “There are 7 institutions that are TRAC eligible,” Doctor LeBeau (explaining TREC/TREC-eligible institution rules).

Next steps
- Staff will negotiate award contracts and execute them under the authority delegated to the CEO and CPRIT staff. The agency will publish FY26 RFAs approved at the meeting and conduct outreach for new mechanisms (including RFAs focused on clinical trial capacity and workforce development in rural/underserved communities).","The oversight committee approved Program Integration Committee recommendations of 47 academic research awards requesting $69.7 million and discussed adding early-onset cancer as a program priority and geographic/recruitment strategies for Texas institutions.",{"_33":101,"_35":36,"_37":38,"_39":102,"_41":103,"_43":104,"_45":105,"_47":106,"_49":107,"_51":108,"_53":109,"_55":56,"_57":58,"_59":110,"_61":62,"_63":64,"_65":111,"_67":68,"_69":70,"_71":72,"_73":74,"_75":74},6528091,"CPRIT oversight committee approves FY25 awards, product development supplements, prevention grants and $300 million bond authorization",4474,98000,4572000,"/Search/View?dp=1&key=3473882-e12be34b17c77ae4df68cebf414939ff&start=98&end=4572","https://assets.pipeline.soar.com/3473882-e12be34b17c77ae4df68cebf414939ff/thumbnail_98000.jpg","/articles/6528091/Texas/CPRIT-oversight-committee-approves-FY25-awards-product-development-supplements-prevention-grants-and-300-million-bond-authorization","https://secure.pipeline.soar.com/6528091-01d464e7fe11ad103454131a91480faf/orig.mp4?Expires=1770995352&Signature=KXHhELXk3wsam8Sg0YivxxNT3qcVSVZcHXNooMhuNptWcjCb38Pt7vnVgQxqyXWxo79UCusTpiamhtKyFpx3fBuZgq6t0e54HAHWnJBW4YQrOKzPRPBPojgrfAnGuQqzWEd9CFQhYhet-LAGM1AGrlzVFrn1qylMDqxWmWR~Wp-kxUzbZ3yn5tAKukwkqZMcNR6z5FdpA6JF4HCaJFgwq1nPGVKc1O6iDih8pEW5rwGItZMGgtrnhUnueYET2KIwwBgcYcEwwDXYrqv9kQNlKVTLzukzh5rktelyINtiX9Dm2zgNh-gqz7Rq5nYRYHNJ6WcYRX7NNuOxC60SsgOi1g__&Key-Pair-Id=KUT5TJCACFTXG","The Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee voted on a package of awards, contract delegations and financing on May 21 during its regular meeting in Austin.

Members approved the academic research program's slate of 47 awards requesting $69.7 million, approved six prevention awards, and approved a product-development supplemental slate funded from unused FY25 product-development dollars. The committee also delegated contract negotiation authority to the CEO and CPRIT staff for the approved awards and authorized the CEO to sign contracts on behalf of CPRIT. Members approved an agency request to authorize up to $300 million in bond financing for fiscal year 2026 through the Texas Public Finance Authority to fund prior-year awards and administrative expenses.

Why this matters: The votes move funding and contracting actions from recommendation to execution and free the agency to begin negotiating awards and contract terms for grantees and product-development companies. The bond authorization sets the finance capacity CPRIT intends to use next fiscal year to support previously approved grants and operations.

What the committee approved and related actions
- Academic research: The committee approved the Program Integration Committee's recommendations for FY25 (47 awards, $69.7 million). Doctor Rosenfeld publicly reported a conflict of interest on RP250601 and did not vote on that recommendation; the remainder of the academic slates passed by the required two-thirds of members present.
- Prevention: The committee approved six prevention grant recommendations from the Prevention Integration Committee and delegated contract negotiation and signature authority to the CEO and staff.
- Product development: The committee approved eight supplemental product-development recommendations (using about $10 million of carryover funds) and delegated contract negotiation/signature authority; the chair also authorized advanced payments to the eight companies upon contract execution and tranche completion.
- Contracts and operations: The committee approved renewal of the grant-management support services contract with General Dynamics Information Technology (GDIT) for FY26 and authorized staff to contract with a venue for the Innovation in X conference for up to $350,000.
- Audit and finance: The committee approved internal audit reports (post-award grant monitoring; non-grant expenditures; purchase card advisory) and accepted the chief financial officer's revenues update. The oversight committee approved a bond issuance resolution authorizing TPFA financing of up to $300 million for FY26.

Quotes
- “We will also have the university advisory committee presentation…including $93,000,000 in awards,” Chief Executive Officer’s report (CEO report). (excerpted from CEO report delivered by Ms. Doyle)
- “I will note for the record that Doctor Rosenfeld did not vote on this recommendation,” Chair (recording Rosenfeld’s recusal on RP250601).

Next steps and implementation notes
- Staff were authorized to negotiate contracts and sign on CPRIT’s behalf; execution and tranche milestones will govern disbursements.
- The bond resolution will be transmitted to the Texas Public Finance Authority to support financing in FY26.

Votes at a glance (formal motions recorded in the transcript):
- Approve minutes of Feb. 19 and March 21 oversight committee meetings — motion carried.
- Approve PIC academic research recommendations for RP250601 (separate vote; Doctor Rosenfeld recused) — motion carried.
- Approve PIC remaining academic research 46 recommendations — motion carried.
- Delegate contract negotiation/signature authority to CEO and staff for academic awards — motion carried.
- Approve FY26 academic research RFAs as presented — motion carried.
- Approve PIC prevention recommendations (6 awards) and delegate negotiation/signature authority — motion carried.
- Approve product development supplemental grants (DP250167 separately noted for conflict reporting) and remaining 7 supplemental awards — motions carried; delegated negotiation/signature authority for product-development awards — motion carried.
- Authorize CPRIT to disperse advanced payments to the eight product development award recipients upon contract execution and tranche satisfaction — motion carried.
- Approve internal audit reports (post-award grant monitoring, non-grant expenditures, purchase-card advisory) — motion carried.
- Approve renewal of GDIT grant-management support services contract for FY26 — motion carried.
- Authorize contracting for Innovation in X conference venue (not-to-exceed $350,000) — motion carried.
- Approve fiscal year 2026 bond issuance resolution requesting up to $300 million from TPFA — motion carried.

Sources and provenance: See provenance entries linked to the transcript for the meeting’s CEO report, PIC presentations, prevention presentations, product development presentation, internal audit and CFO reports, and all recorded motions and votes.","The Cancer Prevention and Research Institute of Texas oversight committee voted to approve multiple grant award slates across academic research, prevention and product development, authorized staff to negotiate and sign contracts, and approved a $300 million bond resolution to support grants and agency operations.","actionData","errors"]

Article not found

CPRIT approves six prevention awards to expand screening, navigation and HPV vaccination in underserved Texas areas

CPRIT awards supplemental product-development funding to eight companies; OncoResponse equity tranche contingent on clinical milestone

CPRIT approves 47 academic research awards totaling $69.7 million; committee debates early-onset cancer priorities

CPRIT oversight committee approves FY25 awards, product development supplements, prevention grants and $300 million bond authorization